JP2019526595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526595A5 JP2019526595A5 JP2019512763A JP2019512763A JP2019526595A5 JP 2019526595 A5 JP2019526595 A5 JP 2019526595A5 JP 2019512763 A JP2019512763 A JP 2019512763A JP 2019512763 A JP2019512763 A JP 2019512763A JP 2019526595 A5 JP2019526595 A5 JP 2019526595A5
- Authority
- JP
- Japan
- Prior art keywords
- cti
- antibody
- kinase
- delta inhibitor
- ubrituximab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385723P | 2016-09-09 | 2016-09-09 | |
| US62/385,723 | 2016-09-09 | ||
| PCT/US2017/050825 WO2018049263A1 (en) | 2016-09-09 | 2017-09-08 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526595A JP2019526595A (ja) | 2019-09-19 |
| JP2019526595A5 true JP2019526595A5 (enExample) | 2020-10-15 |
Family
ID=59969229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512763A Pending JP2019526595A (ja) | 2016-09-09 | 2017-09-08 | 血液癌を治療するための抗ｃｄ２０抗体、ｐｉ３キナーゼ−デルタ阻害剤および抗ｐｄ−１抗体または抗ｐｄ−ｌ１抗体の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190247399A1 (enExample) |
| EP (1) | EP3509634A1 (enExample) |
| JP (1) | JP2019526595A (enExample) |
| KR (1) | KR20190068521A (enExample) |
| CN (1) | CN110191720A (enExample) |
| AU (1) | AU2017322501A1 (enExample) |
| BR (1) | BR112019004185A2 (enExample) |
| CA (1) | CA3035976A1 (enExample) |
| CL (1) | CL2019000585A1 (enExample) |
| EA (1) | EA201990374A1 (enExample) |
| IL (1) | IL265194A (enExample) |
| MX (1) | MX2019002728A (enExample) |
| WO (1) | WO2018049263A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3478723T3 (fi) | 2016-06-29 | 2026-03-17 | Checkpoint Therapeutics Inc | Pd-l1-spesifisiä vasta-aineita ja niiden käyttömenetelmiä |
| PT3448859T (pt) | 2017-03-20 | 2019-10-25 | Forma Therapeutics Inc | Composições de pirrolopirrole como ativadores de piruvato quinase (pkr). |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| WO2020191022A1 (en) * | 2019-03-18 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 9x |
| WO2021009509A1 (en) * | 2019-07-15 | 2021-01-21 | Johnson Matthey Public Limited Company | Amorphous umbralisib monotosylate |
| CN114615977B (zh) | 2019-09-19 | 2025-01-14 | 诺沃挪第克健康护理股份公司 | 丙酮酸激酶r(pkr)活化组合物 |
| CN117222413A (zh) * | 2021-02-10 | 2023-12-12 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| KR20240155263A (ko) * | 2022-02-28 | 2024-10-28 | 재스퍼 테라퓨틱스 인코포레이티드 | 병든 조혈 줄기 세포를 고갈시키기 위한 조성물 및 방법 |
| CN115141092A (zh) * | 2022-07-27 | 2022-10-04 | 诚达药业股份有限公司 | 一种抗淋巴瘤药物相关化合物的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| WO2009055343A2 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| PT2496567T (pt) | 2009-11-05 | 2017-11-15 | Rhizen Pharmaceuticals S A | Novos moduladores de quinase benzopiran |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| EP3939613A1 (en) * | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising pd-1 agonist |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| KR101988079B1 (ko) | 2012-07-04 | 2019-06-11 | 리젠 파마슈티컬스 소시에떼 아노님 | 선택적 pi3k 델타 억제제 |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| US9694071B2 (en) * | 2012-11-02 | 2017-07-04 | Tg Therapeutics, Inc. | Combination of anti-CD20 antibody and PI3 kinase selective inhibitor |
| CA2949932C (en) | 2014-05-27 | 2021-08-10 | Rhizen Pharmaceuticals Sa | Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations |
| SI3179992T1 (sl) * | 2014-08-11 | 2022-09-30 | Acerta Pharma B.V. | Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1 |
| EP3191126B1 (en) * | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
-
2017
- 2017-09-08 MX MX2019002728A patent/MX2019002728A/es unknown
- 2017-09-08 KR KR1020197008508A patent/KR20190068521A/ko not_active Ceased
- 2017-09-08 EP EP17772801.1A patent/EP3509634A1/en not_active Withdrawn
- 2017-09-08 EA EA201990374A patent/EA201990374A1/ru unknown
- 2017-09-08 WO PCT/US2017/050825 patent/WO2018049263A1/en not_active Ceased
- 2017-09-08 CA CA3035976A patent/CA3035976A1/en not_active Abandoned
- 2017-09-08 JP JP2019512763A patent/JP2019526595A/ja active Pending
- 2017-09-08 BR BR112019004185A patent/BR112019004185A2/pt not_active IP Right Cessation
- 2017-09-08 US US16/331,407 patent/US20190247399A1/en not_active Abandoned
- 2017-09-08 AU AU2017322501A patent/AU2017322501A1/en not_active Abandoned
- 2017-09-08 CN CN201780066399.5A patent/CN110191720A/zh active Pending
-
2019
- 2019-03-06 IL IL265194A patent/IL265194A/en unknown
- 2019-03-07 CL CL2019000585A patent/CL2019000585A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526595A5 (enExample) | ||
| Nagelkerke et al. | Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2019506403A5 (enExample) | ||
| US12447150B2 (en) | Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy | |
| JP2022172480A (ja) | 治療組成物、組み合わせ、及び使用方法 | |
| RU2738934C2 (ru) | Способы лечения рака с использованием апилимода | |
| JP2019517485A5 (enExample) | ||
| JP2020505433A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| RU2016148927A (ru) | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства | |
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2017506227A5 (enExample) | ||
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| JP2012509889A5 (enExample) | ||
| JP2011529968A5 (enExample) | ||
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JPWO2020111018A5 (enExample) | ||
| JP2017536408A5 (enExample) | ||
| JP2018503610A5 (enExample) | ||
| JP2019508433A (ja) | Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法 | |
| JP2017537927A5 (enExample) | ||
| JP2018519300A5 (enExample) | ||
| Iratni et al. | Sildenafil in combination therapy against cancer: a literature review | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 |